HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bortolotti, U. Articles by Gallucci, V. Search for Related Content PubMed PubMed Citation Articles by Bortolotti, U. Articles by Gallucci, V.

The Journal of Thoracic and Cardiovascular Surgery, Vol 97, 415-420, Copyright © 1989 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

The Hancock II porcine bioprosthesis. A preliminary report

U Bortolotti, A Milano, A Mazzucco, F Guerra, A Magni, F Santini and V Gallucci
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.

From May 1983 to July 1987 a total of 153 Hancock II porcine bioprostheses have been implanted in 130 patients with a mean age of 59 +/- 8 years (range 29 to 76 years). Mitral valve replacement was performed in 72 patients, aortic valve replacement in 35, and mitral- aortic valve replacement in 23. Cumulative follow-up of 121 survivors is 223 patient-years and 100% complete (range 0.4 to 4.5 years). The actuarial survival rate at 4 years is 88% +/- 8% for mitral, 86% +/- 7.8% for aortic, and 84% +/- 8% for mitral-aortic valve replacement. Minor thomboembolism occurred in two patients (0.9% +/- 0.6%/pt-yr) with an actuarial freedom from emboli at 4 years of 100% for mitral, 96% +/- 3.7% for aortic, and 91% +/- 8.6% for mitral-aortic valve replacement. Anticoagulant-related hemorrhage occurred in 10 patients (4.4% +/- 1.4%/pt-yr) with an actuarial freedom at 4 years of 90% +/- 4.8% for mitral, 89% +/- 5.8% for aortic, and 84% +/- 10.6% for mitral- aortic valve replacement. Failure of the porcine bioprosthesis was observed in three patients with an actuarial freedom at 4 years of 96% +/- 3.6% for aortic, 91% +/- 8% for mitral, and 91% +/- 8.6% for mitral- aortic valve replacement. Actuarial freedom from all porcine bioprosthesis-related complications at 4 years is 85.7% +/- 6.6% for aortic, 79% +/- 9% for mitral, and 70% +/- 13% for mitral-aortic valve replacement. No instances of primary tissue failure occurred.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				U. Bortolotti, A. Milano, G. Thiene, and A. Mazzucco Original expectations of the Hancock valve and 20 years of clinical reality Eur. J. Cardiothorac. Surg., January 1, 1992; 6(suppl_1): S75 - S78. [Abstract] [PDF]

				M. Valente, M. Minarini, A.F. Maizza, U. Bortolotti, and G. Thiene Heart valve bioprosthesis durability: a challenge to the new generation of porcine valves Eur. J. Cardiothorac. Surg., January 1, 1992; 6(suppl_1): S82 - S90. [Abstract] [PDF]